Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Group weighs push to switch the pill OTC

This article was originally published in The Tan Sheet

Executive Summary

A coalition of women's health experts hopes to meet with FDA "in the next few months to discuss the regulatory pathway" for a potential OTC switch of oral contraceptives. Ibis Reproductive Health, which coordinates the Oral Contraceptives Over-the-Counter Working Group, said July 9 it is interested in moving oral contraceptives OTC "as a way to increase access to ECs especially for women who now face barriers to access." Ibis said the coalition is talking with potential partners about what regulatory and research milestones must be reached to switch the prescription drugs and is working to ensure that research needed for a switch, including label comprehension and actual use studies, will address broader questions about women's access to and information about the full range of contraceptive methods. The coalition, which first met in 2004, also is working to change Medicaid policy to cover all OTC contraceptive methods

You may also be interested in...



Device Week, 27 February 2020 – The Risky Business Of Bringing ISO 14971:2019 Into Quality Systems

On this week’s podcast, executive editor Shawn M. Schmitt shares expert tips and advice on how device makers can integrate the recently revised international risk management standard ISO 14971 into their quality systems.

Start-Up Snapshot: Alpha Tau Hopes For A Breakthrough In Radiotherapy

Alpha Tau is looking to change the global radiation therapy paradigm. The Israeli start-up is developing Alpha DaRT, a novel technology for delivering alpha radiation for local tumor destruction.

Faster Please: Alnylam, Eiger & BioCryst Want Quick EMA Reviews

Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.

Topics

UsernamePublicRestriction

Register

PS104291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel